- Joined
- Jul 18, 2012
- Messages
- 312
On 26.02.2015 the Advisory Committee on Dangerous Pathogens met to review the issue of MAP in Crohn's disease for the first time since 2005. This review was requested by Jeremy Hunt (Secretary of State for Health). Their report has just been published online and you can read it on our news page here:
http://crohnsmapvaccine.com/review-...ubsp-paratuberculosis-map-and-crohns-disease/
The original source of this document is:
https://www.gov.uk/government/groups/advisory-committee-on-dangerous-pathogens
You will find it under 'Minutes' by clicking on 'Minutes, papers and agendas'
Dr Irene Grant, commissioned to write the report, is a senior lecturer in Microbiology and food safety at Queens University Belfast. Whilst she maintains that 'it is difficult to draw firm conclusions about MAP in CD at present', she does highlight the following statement from Dr Ingrid Olsen (Norwegian MAP expert): 'Together with all the genetic susceptibility data emerging over the last decade, it is very hard to reject the hypothesis of mycobacteria being involved in the development of CD in at least a sub-cohort of patients'. Her report also identifies, specifically in regard to MAP testing, that 'further research is clearly needed'.
http://crohnsmapvaccine.com/review-...ubsp-paratuberculosis-map-and-crohns-disease/
The original source of this document is:
https://www.gov.uk/government/groups/advisory-committee-on-dangerous-pathogens
You will find it under 'Minutes' by clicking on 'Minutes, papers and agendas'
Dr Irene Grant, commissioned to write the report, is a senior lecturer in Microbiology and food safety at Queens University Belfast. Whilst she maintains that 'it is difficult to draw firm conclusions about MAP in CD at present', she does highlight the following statement from Dr Ingrid Olsen (Norwegian MAP expert): 'Together with all the genetic susceptibility data emerging over the last decade, it is very hard to reject the hypothesis of mycobacteria being involved in the development of CD in at least a sub-cohort of patients'. Her report also identifies, specifically in regard to MAP testing, that 'further research is clearly needed'.